AzurRx BioPharma, Inc. — Form 10-Q summary
Entity note: The request metadata names Gridai Technologies Corp., but the filing identifies the registrant as AzurRx BioPharma, Inc. (Nasdaq: AZRX). This summary reflects the filing provided.
Business context and reporting period
The filing covers the quarter and nine months ended September 30, 2019. AzurRx is a clinical-stage biotechnology company developing non-systemic biologics for gastrointestinal disorders. Its lead candidate, MS1819-SD, is being developed for exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis (CF); its beta-lactamase program remains preclinical. The company reported no approved products or product-sale revenue.
Financial performance and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | None reported from product sales | |||
| Research and development expense | $2.21 million | $1.17 million | $7.07 million | $3.77 million |
| General and administrative expense | $1.87 million | $1.32 million | $6.55 million | $5.40 million |
| Operating loss | $4.08 million | $2.57 million | $13.62 million | $9.41 million |
| Net loss | $4.19 million | $2.57 million | $13.90 million | $9.51 million |
| Basic and diluted loss per share | $(0.17) | $(0.15) | $(0.66) | $(0.64) |
| Net cash used in operating activities | Not provided by quarter | $10.81 million | $7.53 million |
At September 30, 2019, cash was $1.55 million; current assets were $3.73 million and current liabilities were $5.82 million, yielding reported negative working capital of approximately $2.09 million. Total assets were $9.44 million, total liabilities $6.23 million, and stockholders’ equity $3.20 million. Convertible debt was $1.95 million net of discount, with $2.00 million principal issued in 2019. The filing reports no product revenue, so operating margins are not meaningful.
Cash increased by $0.47 million over the nine-month period, primarily because $11.30 million of financing cash inflows more than offset operating and investing outflows. Financing included approximately $9.49 million from 2019 public stock offerings and $2.00 million of ADEC convertible notes. Shares outstanding increased to 26.16 million from 17.70 million at year-end 2018.
Changes versus the prior comparable period
- Nine-month net loss rose by $4.38 million, about 46%; Q3 net loss rose by $1.62 million, about 63%.
- Nine-month R&D expense increased by $3.29 million, primarily reflecting U.S. R&D operations and the OPTION clinical study. Management expected R&D spending to rise as trials advance.
- Nine-month G&A expense increased by $1.15 million, including higher personnel and investor-relations costs and a $367,908 cyber-fraud loss.
- Operating cash use increased by $3.28 million year over year. Cash at quarter-end was below the $4.43 million reported at September 30, 2018.
- Additional equity financing expanded the share count, while the company also issued convertible debt and incurred higher interest expense.
Outlook, risks, contingencies, and unusual items
- Clinical outlook: The company reported that 32 adults completed the OPTION study. At 2.2 grams per day, approximately half had CFA results reaching non-inferiority to standard porcine enzyme replacement therapy; nitrogen absorption was 93% versus 97% in the PERT arm. The study was not powered for statistical significance. Management planned FDA discussions on a subsequent trial, including higher doses and/or enteric-coated capsules. The CF Foundation’s safety monitoring board reported no safety concerns and supported proceeding to a four-gram dose in a planned Phase 2 trial.
- Combination trial: First patients were dosed in October 2019 in a Phase 2 study combining MS1819-SD with PERT in severe CF-related EPI; approximately 24 patients were planned, with completion anticipated in 2020.
- Going concern: The company states that substantial doubt exists about its ability to continue as a going concern. It had significant losses, negative operating cash flows, negative working capital, and an accumulated deficit of $61.41 million. Management said available cash would not fund working-capital needs beyond the next 12 months and that additional financing is required.
- Post-quarter financing arrangement: On November 13, 2019, Lincoln Park committed to purchase up to $15 million of common stock, subject to conditions and at the company’s discretion over a 30-month period after registration effectiveness. The company agreed to issue 487,168 shares for the commitment; the facility does not guarantee that the full amount will be raised.
- Nasdaq listing: The company received a November 1, 2019 notice for failure to meet the $1.00 minimum bid-price requirement. Its listing remained effective, but compliance was required within the stated period, with potential delisting consequences if unresolved.
- Cyber fraud: A hacker impersonating a vendor redirected $418,765. The company recovered $50,858 and recorded a $367,908 loss; management said further recovery was uncertain. Payment-change controls and employee cybersecurity training were added.
- Mayoly asset purchase: The company acquired MS1819-SD rights in March 2019, issuing shares and agreeing to cash and share milestone payments. The filing recorded $3.80 million in patent assets and reported amounts due to Mayoly.
- Other risks: French R&D tax credits were under examination by French tax authorities in the normal course. The company also disclosed that use of U.S. tax-loss carryforwards could be limited by an ownership change.
- Management changes: CEO James Sapirstein began under a new employment agreement on October 8, 2019; former CEO Johan Spoor resigned that day. CFO Maged Shenouda’s resignation, effective November 30, 2019, was disclosed after quarter-end.
Most important facts for investors to verify
- Confirm the registrant’s identity: the supplied filing is for AzurRx BioPharma, not Gridai Technologies Corp.
- Review the full OPTION study data and subsequent FDA feedback, trial design, dose, and timing; the reported efficacy findings were not statistically powered.
- Assess cash runway, monthly cash use, and the likelihood and terms of additional financing given the going-concern warning.
- Track potential dilution from the Lincoln Park facility, outstanding warrants and options, and Mayoly milestone shares.
- Monitor Nasdaq bid-price compliance, tax-credit examination outcomes, and any further recovery of the cyber-fraud funds.